TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vectus Biosystems Limited ( (AU:VBS) ) just unveiled an announcement.
Vectus Biosystems Limited announced progress in its commercialization efforts, particularly with its lead compound VB0004, which has shown safety and tolerability in Phase Ia and Ib trials. The company signed a binding term sheet with XORTX Therapeutics for the sale of its VB4-P5 compound, which will provide Vectus with shares in XORTX, allowing continued interest in the compound’s development without further financial contributions. This strategic move is expected to enhance shareholder value and expand opportunities in the pharmaceutical market.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited operates in the biotechnology industry, focusing on the development and commercialization of small therapeutic molecules targeting fibrotic diseases. The company is known for its drug library, including lead compounds like VB0004, and aims to partner with pharmaceutical companies for licensing opportunities.
Average Trading Volume: 88,110
Technical Sentiment Signal: Hold
Current Market Cap: A$10.4M
Find detailed analytics on VBS stock on TipRanks’ Stock Analysis page.